Skip to Content

Cefoperazone Disease Interactions

There are 7 disease interactions with cefoperazone:

Major

Cephalosporins (Includes Cefoperazone) ↔ Hypoprothrombinemia

Severe Potential Hazard, Moderate plausibility

Applies to: Liver Disease, Coagulation Defect, Vitamin K Deficiency, Thrombocytopenia, Thrombocytopathy, Malnourished, Malabsorption Syndrome, Bleeding

Hypoprothrombinemia, with or without bleeding, has been reported rarely with various cephalosporins, particularly those containing an N-methylthiotetrazole (NMTT) side chain (cefamandole, cefmetazole, cefoperazone, cefotetan). The sulfhydryl group of this side chain is suspected of interfering with the hepatic synthesis of prothrombin. Risk factors include advanced age, debility, vitamin K deficiency, malnutrition, malabsorption, and severe renal or hepatobiliary impairment. Therapy with cephalosporins containing the NMTT side chain should be administered cautiously in patients with any of these risk factors and/or significant active bleeding or a hemorrhagic diathesis. Prophylactic administration of vitamin K may be indicated in some patients, especially when intestinal sterilization and surgical procedures are performed.

References

  1. Alitalo R, Ruutu M, Valtonen V, et al "Hypoprothrombinaemia and bleeding during administration of cefamandole and cefoperazone." Ann Clin Res 17 (1985): 116-9
  2. Sanburg AL, Hughes JD, Nichols C "Antibiotic-induced hypoprothrombinaemia." Med J Aust 143 (1985): 387-8
  3. Parker SW, Baxter J, Beam TR "Cefoperazone-induced coagulopathy." Lancet 1 (1984): 1016
  4. Kline SS, Mauro VF, Forney RB Jr, et al "Cefotetan-induced disulfiram-type reactions and hypoprothrombinemia." Antimicrob Agents Chemother 31 (1987): 1328-31
  5. Osborne JC "Hypoprothrombinemia and bleeding due to cefoperazone." Ann Intern Med 102 (1985): 721-2
  6. Shearer MJ, Bechtold H, Andrassy K, Koderisch J, McCarthy PT, Trenk D, Jahnchen E, Ritz E "Mechanism of cephalosporin-induced hypoprothrombinemia: relation to cephalosporin side chain, vitamin K metabolism, and vitamin K status." J Clin Pharmacol 28 (1988): 88-95
  7. Natelson EA, Brown CH, 3d Bradshaw MW, Alfrey CP, Jr Williams TW, Jr "Influence of cephalosporin antibiotics on blood coagulation and platelet function." Antimicrob Agents Chemother 9 (1976): 91-3
  8. Yangco BG, Palumbo JA, Nolen T, et al "Comparative multicentre evaluation of the safety and efficacy of ceftazidime versus cefamandole for pneumonia." J Antimicrob Chemother 18 (1986): 521-9
  9. O'Donnell D "Hypoprothrombinaemia associated with use of cephamandole." Aust N Z J Surg 61 (1991): 471-2
  10. D'Elia JA, Kaldany A, Miller DG, et al "Moxalactam bleeding and renal insufficiency." JAMA 249 (1983): 1565
  11. Sanburg AL, Hughes JD, Nichols C "Antibiotic-induced hypoprothrombinaemia." Med J Aust 143 (1985): 387-8
  12. Wurtz RM, Sande MA "Cefotetan and coagulopathy." J Infect Dis 160 (1989): 555-6
  13. Brown RB, Klar J, Lemeshow S, Teres D, Pastides H, Sands M "Enhanced bleeding with cefoxitin or moxalactam." Arch Intern Med 146 (1986): 2159-64
  14. Bertino JS, Kozak AJ, Reese RE, Chiarello LA "Hypoprothrombinemia associated with cefamandole use in a rural teaching hospital." Arch Intern Med 146 (1986): 1125-8
  15. "Product Information. Cefobid (cefoperazone)." Roerig Division, New York, NY.
  16. Haubenstock A, Schmidt P, Zazgornik J, Balcke P, Kopsa H "Hypoprothrombinaemic bleeding associated with ceftriaxone." Lancet 1 (1983): 1215-6
  17. Holt J "Hypoprothrombinemia and bleeding diathesis associated with cefotetan therapy in surgical patients." Arch Surg 123 (1988): 523
  18. "Product Information. Zefazone (cefmetazole)." Pharmacia and Upjohn, Kalamazoo, MI.
  19. "Product Information. Mandol (cefamandole)." Lilly, Eli and Company, Indianapolis, IN.
  20. Tibbitts JS, Lipsky JJ "Effect of biliary diversion on the ability of cefamandole to inhibit vitamin K metabolism." Drug Metabol Drug Interact 7 (1989): 149-60
  21. Breen GA, Stpeter WL "Hypoprothrombinemia associated with cefmetazole." Ann Pharmacother 31 (1997): 180-4
  22. Meisel S "Hypoprothrombinemia due to cefoperazone." Drug Intell Clin Pharm 18 (1984): 316
  23. Kaiser CW, McAuliffe JD, Barth RJ, Lynch JA "Hypoprothrombinemia and hemorrhage in a surgical patient treated with cefotetan." Arch Surg 126 (1991): 524-5
  24. Andrassy K, Koderisch J, Fritz S, et al "Alteration of hemostasis associated with cefoperazone treatment." Infection 14 (1986): 27-31
  25. Shimanda K, Matsuda T, Inamatsu T, Urayama K "Bleeding secondary to vitamin K deficiency in patients receiving parenteral cephem antibiotics." J Antimicrob Chemother 14 (1984): 325-30
  26. Mueller RJ, Green D, Phair JP "Hypoprothrombinemia associated with cefoperazone therapy." South Med J 80 (1987): 1360-2
  27. Fujita Y, Inoue S, Yorifuji R, et al "Effects of cefotaxime on blood coagulation in patients with renal insufficiency." Drugs 35 (1988): 196-8
  28. Cristiano P "Hypoprothrombinemia associated with cefoperazone treatment." Drug Intell Clin Pharm 18 (1984): 314-6
  29. Shimada K, Matsuda T, Inamatsu T, Urayama K "Bleeding secondary to vitamin K deficiency in patients receiving parenteral cephem antibiotics." J Antimicrob Chemother 14 (1984): 325-30
  30. Riancho JA, Olmos JM, Sedano C "Life-threatening bleeding in a patient treated with cefonicid." Ann Intern Med 123 (1995): 472-3
  31. "Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals, Wilmington, DE.
  32. Fass RJ, Copelan EA, Brandt JT, Moeschberger ML, Ashton JJ "Platelet-mediated bleeding caused by broad-spectrum penicillins." J Infect Dis 155 (1987): 1242-8
  33. Clark J, Hochman R, Rolla A, et al "Coagulopathy associated with the use of cephalosporin or moxalactam antibiotics in acute and chronic renal failure." Clin Exp Dial Apheresis 7 (1983): 177-90
  34. Conjura A, Bell W, Lipsky JJ "Cefotetan and hypoprothrombinemia." Ann Intern Med 108 (1988): 643
  35. Freedy HR, Cetnarowski AB, Lumish RM, Schafer FJ "Cefoperazone-induced coagulopathy." Drug Intell Clin Pharm 20 (1986): 281-3
  36. Lerner PI, Lubin A "Coagulopathy with cefazolin in uremia." N Engl J Med 290 (1974): 1324
  37. Shenkenberg TD, Mackowiak PA, Smith JW "Coagulopathy and hemorrhage associated with cefoperazone therapy in a patient with renal failure." South Med J 78 (1985): 488-9
View all 37 references
Moderate

Antibiotics (Includes Cefoperazone) ↔ Colitis

Moderate Potential Hazard, Moderate plausibility

Applies to: Colitis/Enteritis (Noninfectious)

Pseudomembranous colitis has been reported with most antibacterial agents and may range in severity from mild to life-threatening, with an onset of up to two months following cessation of therapy. Antibiotic therapy can alter the normal flora of the colon and permit overgrowth of Clostridium difficile, whose toxin is believed to be a primary cause of antibiotic- associated colitis. The colitis is usually characterized by severe, persistent diarrhea and severe abdominal cramps, and may be associated with the passage of blood and mucus. The most common culprits are clindamycin, lincomycin, the aminopenicillins (amoxicillin, ampicillin), and the cephalosporins. Therapy with broad-spectrum antibiotics and other agents with significant antibacterial activity should be administered cautiously in patients with a history of gastrointestinal diseases, particularly colitis. There is some evidence that pseudomembranous colitis, if it occurs, may run a more severe course in these patients and that it may be associated with flares in their underlying disease activity. The offending antibiotic(s) should be discontinued if significant diarrhea occurs during therapy. Stool cultures for Clostridium difficile and stool assay for C. difficile toxin may be helpful diagnostically. A large bowel endoscopy may be considered to establish a definitive diagnosis in cases of severe diarrhea.

References

  1. Moriarty HJ, Scobie BA "Pseudomembranous colitis in a patient on rifampicin and ethambutol." N Z Med J 04/23/80 (1980): 294-5
  2. Thomas E, Mehta JB "Pseudomembranous colitis due to oxacillin therapy." South Med J 77 (1984): 532-3
  3. Davies J, Beck E "Recurrent colitis following antibiotic-associated pseudomembranous colitis." Postgrad Med J 57 (1981): 599-601
  4. Saadah HA "Carbenicillin and pseudomembranous enterocolitis." Ann Intern Med 93 (1980): 645
  5. Lyon JA "Imipenem/cilastatin: the first carbapenem antibiotic." Drug Intell Clin Pharm 19 (1985): 894-8
  6. Trexler MF, Fraser TG, Jones MP "Fulminant pseudomembranous colitis caused by clindamycin phosphate vaginal cream." Am J Gastroenterol 92 (1997): 2112-3
  7. Daly JJ, Chowdary KV "Pseudomembranous colitis secondary to metronidazole." Dig Dis Sci 28 (1983): 573-4
  8. Bauwens JE, McFarland LV, Melcher SA "Recurrent clostridium difficile disease following ciprofloxacin use." Ann Pharmacother 31 (1997): 1090
  9. O'Meara TF, Simmons RA "Carbenicillin and pseudomembranous enterocolitis." Ann Intern Med 92 (1980): 440-1
  10. Meadowcroft AM, Diaz PR, Latham GS "Clostridium difficile toxin-induced colitis after use of clindmycin phosphate vaginal cream." Ann Pharmacother 32 (1998): 309-11
  11. Dan M, Samra Z "Clostridium difficile colitis associated with ofloxacin therapy." Am J Med 87 (1989): 479
  12. Milstone EB, McDonald AJ, Scholhamer CF Jr "Pseudomembranous colitis after topical application of clindamycin." Arch Dermatol 117 (1981): 154-5
  13. Harmon T, Burkhart G, Applebaum H "Perforated pseudomembranous colitis in the breast-fed infant." J Pediatr Surg 27 (1992): 744-6
  14. Ehrenpreis ED, Lievens MW, Craig RM "Clostridium difficile-associated diarrhea after norfloxacin." J Clin Gastroenterol 12 (1990): 188-9
  15. Burt RA "A review of the drug events reported by 12,917 patients treated with cephalexin." Postgrad Med J 59 (1983): 47-50,51-3
  16. Cone JB, Wetzel W "Toxic megacolon secondary to pseudomembranous colitis." Dis Colon Rectum 25 (1982): 478-82
  17. Cannon SR, Dyson PH, Sanderson PJ "Pseudomembranous colitis associated with antibiotic prophylaxis in orthopaedic surgery." J Bone Joint Surg Br 70-B (1988): 600-2
  18. Miller DL, Sedlack JD, Holt RW "Perforation complicating rifampin-associated pseudomembranous enteritis." Arch Surg 124 (1989): 1082
  19. Miller SN, Ringler RP "Vancomycin-induced pseudomembranous colitis." J Clin Gastroenterol 9 (1987): 114-5
  20. Calandra GB, Brown KR, Grad LC, et al "Review of adverse experiences and tolerability in the first 2,516 patients treated with imipenem/cilastatin." Am J Med 78 (1985): 73-8
  21. Wang C, Calandra GB, Aziz MA, Brown KR "Efficacy and safety of imipenem/cilastatin: a review of worldwide clinical experience." Rev Infect Dis 7 (1985): s528-36
  22. Osler T, Lott D, Bordley J, et al "Cefazolin-induced pseudomembranous colitis resulting in perforation of the sigmoid colon." Dis Colon Rectum 29 (1986): 140-3
  23. Parry MF, Rha CK "Pseudomembranous colitis caused by topical clindamycin phosphate." Arch Dermatol 122 (1986): 583-4
  24. Clissold SP, Todd PA, Campoli-Richards DM "Imipenem/cilastatin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy." Drugs 33 (1987): 185-241
  25. Pokorney BH, Nichols TW, Jr "Pseudomembranous colitis. A complication of sulfasalazine therapy in a patient with Crohn's colitis." Am J Gastroenterol 76 (1981): 374-6
  26. Bingley PJ, Harding GM "Clostridium difficile colitis following treatment with metronidazole and vancomycin." Postgrad Med J 63 (1987): 993-4
  27. Hutcheon DF, Milligan FD, Yardley JH, Hendrix TR "Cephalosporin-associated pseudomembranous colitis." Am J Dig Dis 23 (1978): 321-6
  28. Sankarankutty M, McGeorge D, Galasko CS "Pseudomembranous colitis following cephradine prophylaxis." Postgrad Med J 58 (1982): 726-8
  29. Gordin F, Gibert C, Schmidt ME "Clostridium difficile colitis associated with trimethoprim-sulfamethoxazole given as prophylaxis for pneumocystis carinii pneumonia." Am J Med 96 (1994): 94-5
  30. Sugarman B "Trimethoprim-sulfamethoxazole, pseudomembranous colitis, and spinal cord injury." South Med J 78 (1985): 711-3
  31. Bernstein L "Adverse reaction to trimethoprim-sulfamethoxazole, with particular reference to long-term therapy." Can Med Assoc J 112 (1975): s96-8
  32. Midtvedt T, Carlstedt-Duke B, Hoverstad T, et al "Influence of peroral antibiotics upon the biotransformatory activity of the intestinal microflora in healthy subjects." Eur J Clin Invest 16 (1986): 11-7
  33. Altamirano A, Bondani A "Adverse reactions to furazolidone and other drugs. A comparative review." Scand J Gastroenterol Suppl 169 (1989): 70-80
  34. Ring FA, Hershfield NB, Machin GA, Scott RB "Sulfasalazine-induced colitis complicating idiopathic ulcerative colitis." Can Med Assoc J 131 (1984): 43-5
  35. Golledge CL, Riley TV "Clostridium difficile-associated diarrhoea after doxycycline malaria prophylaxis." Lancet 345 (1995): 1377-8
  36. Friedman RJ, Mayer IE, Galambos JT, Hersh T "Oxacillin-induced pseudomembranous colitis." Am J Gastroenterol 73 (1980): 445-7
  37. Edlund C, Lidbeck A, Kager L, Nord CE "Effect of enoxacin on colonic microflora of healthy volunteers." Eur J Clin Microbiol 6 (1987): 298-300
  38. Van Ness MM, Cattau EL Jr "Fulminant colitis complicating antibiotic-associated pseudomembranous colitis: case report and review of the clinical manifestations and treatment." Am J Gastroenterol 82 (1987): 374-7
  39. Boriello SP, Jones RH, Phillips I "Rifampicin-associated pseudomembranous colitis." Br Med J 281 (1980): 1180-1
  40. Klinger D, Radford P, Collin J "Pneumoperitoneum without faecal peritonitis in a patient with pseudomembranous colitis." Br Med J 288 (1984): 1271-2
  41. "Multum Information Services, Inc. Expert Review Panel"
  42. Leigh DA, Simmons K, Williams S "Gastrointestinal side effects following clindamycin and lincomycin treatment: a follow up study." J Antimicrob Chemother 6 (1980): 639-45
  43. Hecht JR, Olinger EJ "Clostridium difficile colitis secondary to intravenous vancomycin." Dig Dis Sci 34 (1989): 148-9
  44. Hinton NA "The effect of oral tetracycline HCl and doxycycline on the intestinal flora." Curr Ther Res Clin Exp 12 (1970): 341-52
  45. Brause BD, Romankiewicz JA, Gotz V, Franklin JE Jr, Roberts RB "Comparative study of diarrhea associated with clindamycin and ampicillin therapy." Am J Gastroenterol 73 (1980): 244-8
  46. Edlund C, Brismar B, Nord CE "Effect of lomefloxacin on the normal oral and intestinal microflora." Eur J Clin Microbiol Infect Dis 1 (1990): 35-9
  47. Saginur R, Hawley CR, Bartlett JG "Colitis associated with metronidazole therapy." J Infect Dis 141 (1980): 772-4
View all 47 references
Moderate

Cefoperazone (Includes Cefoperazone) ↔ Renal/Liver Disease

Moderate Potential Hazard, Moderate plausibility

Applies to: Liver Disease, Biliary Obstruction, Renal Dysfunction

Cefoperazone is primarily eliminated by hepatobiliary excretion. In patients with impaired hepatic function and/or biliary obstruction, the half-life of cefoperazone is prolonged 2- to 4-fold but urinary excretion is increased. At usual dosages, adjustments are generally not necessary in either renal or hepatobiliary impairment. However, serum drug concentrations should be monitored if high dosages are used (i.e. > 4 g/day), and the dosage decreased accordingly if drug accumulation occurs. In patients with both hepatic and severe renal impairment, cefoperazone dosage should not exceed 1 to 2 grams per day without close monitoring of serum concentrations.

References

  1. Greenfield RA, Gerber AU, Craig WA "Pharmacokinetics of cefoperazone in patients with normal and impaired hepataic and renal function." Rev Infect Dis 5 (1983): s127-36
  2. Balant L, Dayer P, Rudhardt M, et al "Cefoperazone: pharmacokinetics in humans with normal and impaired renal function and pharmacokinetics in rats." Clin Ther 3 (1980): 50-9
  3. Neu HC "A review and summary of the pharmacokinetics of cefoperazone: a new, extended-spectrum B-lactam antibiotic." Ther Drug Monit 3 (1981): 121-8
  4. Saudek F, Moravek J, Modr Z "Cefoperazone pharmacokinetics in patients with liver cirrhosis: a predictive value of the ujoviridin test." Int J Clin Pharmacol Ther Toxicol 27 (1989): 82-7
  5. Bolton WK, Scheld WM, Spyker DA, Sande MA "Pharmacokinetics of cefoperazone in normal volunteers and subjects with renal insufficiency." Antimicrob Agents Chemother 19 (1981): 821-5
  6. Muder RR, Agarwala S, Mirani A, Gayowski T, Venkataramanan R "Pharmacokinetics of cefoperazone and sulbactam in liver transplant patients." J Clin Pharmacol 42 (2002): 644-50
  7. Cochet B, Belaieff J, Allaz AF, et al "Serum levels and urinary excretion of cefoperazone in patients with hepatic insufficiency." Infection 9 (1981): s37-9
  8. "Product Information. Cefobid (cefoperazone)." Roerig Division, New York, NY.
  9. Boscia JA, Korzeniowski OM, Snepar R, et al "Cefoperazone pharmacokinetics in normal subjects and patients with cirrhosis." Antimicrob Agents Chemother 23 (1983): 385-9
View all 9 references
Moderate

Cefoperazone (Includes Cefoperazone) ↔ Sodium

Moderate Potential Hazard, High plausibility

Applies to: Congestive Heart Failure, Hypertension, Fluid Retention, Hypernatremia

Parenteral cefoperazone sodium contains approximately 34 mg (1.5 mEq) of sodium per each gram of cefoperazone activity. The sodium content should be considered in patients with conditions that may require sodium restriction, such as congestive heart failure, hypertension, and fluid retention.

References

  1. "Product Information. Cefobid (cefoperazone)." Roerig Division, New York, NY.
Moderate

Cephalosporins (Includes Cefoperazone) ↔ Dialysis

Moderate Potential Hazard, High plausibility

Applies to: hemodialysis

Most cephalosporin antibiotics are removed by hemodialysis. Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis. Cefonicid, cefixime, and ceftriaxone are not significantly removed by hemodialysis.

References

  1. Barriere SL, Gambertoglio JG, Alexander DR, et al "Pharmacokinetic disposition of cefonicid in patients with renal failure and receiving hemodialysis." Rev Infect Dis 6 (1984): s809-15
  2. "Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn, Kalamazoo, MI.
  3. Chodos J, Francke EL, Saltzman M, Neu HC "Pharmacokinetics of intravenous cefotaxime in patients undergoing chronic hemodialysis." Ther Drug Monit 3 (1981): 71-4
  4. "Product Information. Claforan (cefotaxime)." Hoechst Marion-Roussel Inc, Kansas City, MO.
  5. Nikolaidis P, Tourkantonis A "Effect of hemodialysis on ceftazidime pharmacokinetics." Clin Nephrol 24 (1985): 142-6
  6. Aziz NS, Gambertoglio JG, Lin ET, Grausz H, Benet LZ "Pharmacokinetics of cephalothin and its metabolite in uremic patients undergoing hemodialysis using an HPLC assay." Jernal Perubatan UKM (Medical Journal, National Univ. of Malaysia) 2 (2) (1980): 82-9
  7. Garcia RL, Santivanez V, Battilana CA "Single-dose pharmacokinetics of ceftriaxone in patients with end-stage renal disease and hemodialysis." Chemotherapy 34 (1988): 261-6
  8. "Product Information. Ceftin (cefuroxime)." Glaxo Wellcome, Research Triangle Park, NC.
  9. "Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb, Princeton, NJ.
  10. "Product Information. Velosef (cephradine)." Apothecon Inc, Plainsboro, NJ.
  11. Reisberg BE, Mandelbaum JM "Cephalexin: absorption and excretion as related to renal function and hemodialysis." Infect Immun 3 (1971): 540-3
  12. Appel GB, Neu HC, Parry MF, et al "Pharmacokinetics of cefamandole in the presence of renal failure and in patients undergoing hemodialysis." Antimicrob Agents Chemother 10 (1976): 623-5
  13. Shyu WC, Pittman KA, Wilber RB, et al "Pharmacokinetics of cefprozil in healthy subjects and patients with renal impairment." J Clin Pharmacol 31 (1991): 362-71
  14. "Product Information. Tazicef (ceftazidime)." SmithKline Beecham, Philadelphia, PA.
  15. Spyker DA, Richmond JD, Scheld WM, Bolton WK "Pharmacokinetics of multiple-dose cefoperazone in hemodialysis patients." Am J Nephrol 5 (1985): 355-60
  16. Ti TY, Fortin L, Kreeft JH, East DS, Ogilvie RI, Somerville PJ "Kinetic disposition of intravenous ceftriaxone in normal subjects and patients with renal failure on hemodialysis or peritoneal dialysis." Antimicrob Agents Chemother 25 (1984): 83-7
  17. "Product Information. Maxipime (cefepime)." Bristol-Myers Squibb, Princeton, NJ.
  18. Matzke GR, Frye RF, Joy MS, Palevsky PM "Determinants of ceftriaxone clearance by continuous venovenous hemofiltration and hemodialysis." Pharmacotherapy 20 (2000): 635-43
  19. "Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc, Deerfield, IL.
  20. "Product Information. Cedax (ceftibuten)." Schering-Plough, Liberty Corner, NJ.
  21. Allaouchiche B, Breilh D, Jaumain H, Gaillard B, Renard S, Saux MC "Pharmacokinetics of cefepime during continuous venovenous hemodiafiltration." Antimicrob Agents Chemother 41 (1997): 2424-7
  22. Hoffler D, Koeppe P, Corcilius M, Przyklink A "Cefpodoxime proxetil in patients with endstage renal failure on hemodialysis." Infection 18 (1990): 157-62
  23. "Product Information. Rocephin (ceftriaxone)." Roche Laboratories, Nutley, NJ.
  24. Spyker DA, Gober LL, Scheld WM, et al "Pharmacokinetics of cefaclor in renal failure: effects of multiple doses and hemodialysis." Antimicrob Agents Chemother 21 (1982): 278-81
  25. "Product Information. Mandol (cefamandole)." Lilly, Eli and Company, Indianapolis, IN.
  26. Weiss LG, Cars O, Danielson BG, et al "Pharmacokinetics of intravenous cefuroxime during intermittent and continuous arteriovenous hemofiltration." Clin Nephrol 30 (1988): 282-6
  27. Garcia MJ, Dominguez-Gil A, Tabernero JM, Molina MD "Pharmacokinetics of cefoxitin during haemofiltration." Eur J Clin Pharmacol 25 (1983): 395-8
  28. Ohkawa M, Okasho A, Motoi I, et al "Elimination kinetics of cefotaxime and desacetylcefotaxime in patients with renal insufficiency and during hemodialysis." Chemotherapy 29 (1983): 4-12
  29. Bunke CM, Aronoff GR, Luft FC "Pharmacokinetics of common antibiotics used in continuous ambulatory peritoneal dialysis." Am J Kidney Dis 3 (1983): 114-7
  30. "Product Information. Omnicef (cefdinir)." Parke-Davis, Morris Plains, NJ.
  31. Gambertoglio JG, Aziz NS, Lin ET, et al "Cefamandole kinetics in uremic patients undergoing hemodialysis." Clin Pharmacol Ther 26 (1979): 592-9
  32. "Product Information. Cefadyl (cephapirin)." Apothecon Inc, Plainsboro, NJ.
  33. "Product Information. Lorabid (loracarbef)." Lilly, Eli and Company, Indianapolis, IN.
  34. "Product Information. Keflex (cephalexin)." Dista Products Company, Indianapolis, IN.
  35. Craig CP, Rifkin SI "Pharmacokinetics and hemodialyzability of cefazolin in uremic patients." Clin Pharmacol Ther 19 (1976): 825-9
  36. Gartenberg G, Meyers BR, Hirschman SZ, Srulevitch E "Pharmacokinetics of cefaclor in patients with stable renal impairment, and patients undergoing haemodialysis." J Antimicrob Chemother 5 (1979): 465-70
  37. Browning MJ, Holt HA, White LO, et al "Pharmacokinetics of cefotetan in patients with end-stage renal failure on maintenance dialysis." J Antimicrob Chemother 18 (1986): 103-6
  38. Gabutti L, TaminelliBeltraminelli L, Marone C "Clearance of ceftriaxone during haemodialysis using cuprophane, haemophane and polysulfone dialysers." Eur J Clin Pharmacol 53 (1997): 123-6
  39. Hasegawa H, Imada A, Horiuchi A, et al "Pharmacokinetics of cefotaxime in patients undergoing haemodialysis and continuous ambulatory peritoneal dialysis." J Antimicrob Chemother 14 Suppl (1984): 135-42
  40. Ohkawa M, Nakashima T, Shoda R, et al "Pharmacokinetics of ceftazidime in patients with renal insufficiency and in those undergoing hemodialysis." Chemotherapy 31 (1985): 410-6
  41. "Product Information. Keflin (cephalothin)." Lilly, Eli and Company, Indianapolis, IN.
  42. Garcia MJ, Dominguez-Gil A, Tabernero JM, Roman AB "Pharmacokinetics of cefoxitin in patients undergoing hemodialysis." Int J Clin Pharmacol Biopharm 17 (1979): 366-70
  43. Campillo JA, Lanao JM, Dominguez-Gil A, et al "Pharmacokinetics of cefamandole in patients undergoing hemodialysis." Int J Clin Pharmacol Biopharm 17 (1979): 416-20
  44. Madhavan T, Yaremchuk K, Levin N, et al "Effects of renal failure and dialysis on cefazolin pharmacokinetics." Antimicrob Agents Chemother 8 (1975): 63-6
  45. McCloskey RV, Terry EE, McCracken AW, Sweeney MJ, Forland MF "Effect of hemodialysis and renal failure on serum and urine concentrations of cephapirin sodium." Antimicrob Agents Chemother 1 (1972): 90-3
  46. "Product Information. Cefobid (cefoperazone)." Roerig Division, New York, NY.
  47. "Product Information. Ancef (cefazolin)." SmithKline Beecham, Philadelphia, PA.
  48. Johnson CA, Ateshkadi A, Zimmerman SW, Hughes GS, Craig WA, Carey PM, Borin MT "Pharmacokinetics and ex vivo susceptibility of cefpodoxime proxetil in patients receiving continuous ambulatory peritoneal dialysis." Antimicrob Agents Chemother 37 (1993): 2650-5
  49. Kroh UF, Lennartz H, Edwards DJ, Stoeckel K "Pharmacokinetics of ceftriaxone in patients undergoing continuous veno-venous hemofiltration." J Clin Pharmacol 36 (1996): 1114-9
  50. Davis GM, Forland SC, Cutler RE "Serum and dialysate concentrations of cephalexin following repeated dosing in CAPD patients." Am J Kidney Dis 6 (1985): 177-80
  51. "Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc, Baltimore, MD.
  52. "Product Information. Mefoxin (cefoxitin)." Merck & Co, Inc, West Point, PA.
  53. Gabutti L, Taminelli-Beltraminelli L, Marone C "Clearance of ceftriaxone during haemodialysis using cuprophane, haemophane and polysulfone dialysers." Eur J Clin Pharmacol 53 (1997): 123-6
  54. "Product Information. Monocid (cefonicid)." SmithKline Beecham, Philadelphia, PA.
  55. "Product Information. Ceclor (cefaclor)." Lilly, Eli and Company, Indianapolis, IN.
  56. Berman SJ, Boughton WH, Sugihara JG, et al "Pharmacokinetics of cefaclor in patients with end stage renal disease and during hemodialysis." Antimicrob Agents Chemother 14 (1978): 281-3
  57. "Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals, Wilmington, DE.
  58. Cohen D, Appel GB, Scully B, Neu HC "Pharmacokinetics of ceftriaxone in patients with renal failure and in those undergoing hemodialysis." Antimicrob Agents Chemother 24 (1983): 529-32
  59. Bunke CM, Aronoff GR, Brier ME, et al "Cefazolin and cephalexin kinetics in continuous ambulatory peritoneal dialysis." Clin Pharmacol Ther 33 (1983): 66-72
  60. Ahern MJ, Finkelstein FO, Andriole VT "Pharmacokinetics of cefamandole in patients undergoing hemodialysis and peritoneal dialysis." Antimicrob Agents Chemother 10 (1976): 457-61
  61. Brogard JM, Pinget M, Brandt C, Lavillaureix J "Pharmacokinetics of cefazolin in patients with renal failure: special reference to hemodialysis." J Clin Pharmacol 17 (1977): 225-30
  62. "Product Information. Cefizox (ceftizoxime)." Fujisawa, Deerfield, IL.
  63. Bailey RR, Gower PE, Dash CH "The effect of impairment of renal function and haemodialysis on serum and urine levels of cephalexin." Postgrad Med J 46 (1970): 60-4
  64. "Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb, Princeton, NJ.
View all 64 references
Moderate

Cephalosporins (Includes Cefoperazone) ↔ Disulfiram-Like Reaction

Moderate Potential Hazard, Moderate plausibility

Applies to: Alcoholism

Disulfiram-like reactions may occur in patients who consume alcohol within 72 hours after administration of a cephalosporin antibiotic that contains an N-methylthiotetrazole (NMTT) side chain (cefamandole, cefmetazole, cefoperazone, cefotetan). The reaction appears to result from accumulation of acetaldehyde due to inhibition of acetaldehyde dehydrogenase. Therapy with cephalosporins containing the NMTT side chain should be administered cautiously in patients with a history of alcoholism. Patients should be instructed to avoid alcohol-containing products during therapy and up to 72 hours after the last dose.

References

  1. Freundt KJ, Kitson TM "Inactivation of aldehyde dehydrogenase by a putative metabolite of cefamandole." Infection 14 (1986): 44-7
  2. "Product Information. Mandol (cefamandole)." Lilly, Eli and Company, Indianapolis, IN.
  3. "Product Information. Cefobid (cefoperazone)." Roerig Division, New York, NY.
  4. Umeda S, Arai T "Disulfiram-like reaction to moxalactam after celiac plexus alcohol block." Anesth Analg 64 (1985): 377
  5. McMahon FG "Disulfiram-like reaction to a cephalosporin." JAMA 243 (1980): 2397
  6. "Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals, Wilmington, DE.
  7. "Product Information. Zefazone (cefmetazole)." Pharmacia and Upjohn, Kalamazoo, MI.
  8. Reeves DS, Davies AJ "Antabuse effect with cephalosporins." Lancet 2 (1980): 540
  9. Kline SS, Mauro VF, Forney RB Jr, et al "Cefotetan-induced disulfiram-type reactions and hypoprothrombinemia." Antimicrob Agents Chemother 31 (1987): 1328-31
  10. Brown KR, Guglielmo BJ, Pons VG, Jacobs RA "Theophylline elixir, moxalactam, and a disulfiram reaction." Ann Intern Med 97 (1982): 621-2
  11. Foster TS, Raehl CL, Wilson HD "Disulfiram-like reaction associated with a parenteral cephalosporin." Am J Hosp Pharm 37 (1980): 858-9
  12. Freundt KJ, Schreiner E, Christmann-Kleiss U "Cefamandole: a competitive inhibitor of aldehyde dehydrogenase." Infection 13 (1985): 91
View all 12 references
Moderate

Cephalosporins (Includes Cefoperazone) ↔ Liver Disease

Moderate Potential Hazard, Moderate plausibility

Applies to: Liver Disease

Cases of hepatitis have been reported with the use of certain cephalosporins. Transient rise in SGOT, SGPT, and alkaline phosphatase levels have also been observed. Caution and monitoring is recommended when these agents are prescribed to patients with hepatic disorders.

cefoperazone drug Interactions

There are 60 drug interactions with cefoperazone

cefoperazone alcohol/food Interactions

There are 2 alcohol/food interactions with cefoperazone

Drug Interaction Classification

The classifications below are a general guideline only. It is difficult to determine the relevance of a particular drug interaction to any individual given the large number of variables.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No information available.

Do not stop taking any medications without consulting your healthcare provider.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide